What Is Kratom? Why Has the DEA Wanted to Ban It?
By Jennifer Clopton
(Editor’s note: This story was updated on Oct. 12, 2016, with the DEA withdrawing its intent to ban kratom and establishing a public comment period.)
Sept. 19, 2016 — Advocates say the herb kratom offers relief from pain. depression. and anxiety. Scientists say it may hold the key to treating chronic pain and may even be a tool to combat addiction to opioid medications .
But the Drug Enforcement Administration (DEA) was initially moving to ban its sale as of Sept. 30, citing an “imminent hazard to public safety.” The DEA in August announced it would make kratom a Schedule 1 drug — the same as heroin. LSD, marijuana. and ecstasy .
The decision was delayed after members of Congress urged the DEA to delay the ban and give the public a chance to comment.
The DEA has withdrawn its intent to make kratom a Schedule 1 drug and established a public comment period through Dec. 1, according to a preliminary document available on the Federal Register website and set to be published on Oct. 13.
The DEA “has received numerous comments from members of the public challenging the scheduling action and requesting that the agency consider those comments and accompanying information before taking further action,” Chuck Rosenberg, acting administrator, wrote in the preliminary document.
The DEA also has asked the FDA to speed up a previously requested scientific and medical evaluation of kratom and a scheduling recommendation.
The agency says kratom has a high potential for abuse and no current medical use. But its announcement sparked outrage. Opponents rallied in front of the White House against the ban, and more than 142,000 people signed a petition asking the federal government to reconsider.
Some research scientists were among those pushing to reverse the decision, saying a ban will harm their ability to study whether kratom can help treat pain and addiction. In the meantime, users rushed to buy the supplement before it became illegal.
Groups opposing the ban applauded the DEA’s action.
“Everyone needs to understand that this is just the beginning of the fight and much more work remains to be done,” says a joint statement issued by the American Kratom Association and the Botanical Education Alliance. “We cannot and will not rest until the cloud created by the DEA is completely removed.”
Here’s what we know about kratom.
What Is Kratom?
Kratom is a tropical tree in Southeast Asia. Its leaves have been used for hundreds of years to relieve pain. They can be eaten raw, but more often they’re crushed and brewed as tea or turned into capsules, tablets, and liquids.
In low doses, kratom acts as a stimulant. In large amounts, it acts as a sedative, and the DEA says it can lead to psychotic symptoms and psychological addiction. According to the CDC, about 42% of cases of kratom use reported between 2010 and 2015 involved non-life-threatening symptoms that required some treatment. About 7% of exposures were classified as major and life-threatening. The DEA says it knows of 15 kratom-related deaths between 2014 and 2016.
Kratom has been on the DEA’s list of drugs and chemicals of concern for several years. But the DEA notes that its use appears to be going up. Law enforcement agencies across the country seized more kratom in the first half of 2016 than ever before. U.S. poison control centers received 263 calls about kratom in 2015, a tenfold increase from 2010, the CDC says.
How Kratom Works
In mice, kratom targets a part of the brain that responds to drugs like morphine, codeine, and fentanyl. according to a study published earlier this month by Susruta Majumdar, PhD, a researcher at Memorial Sloan Kettering Cancer Center in New York. These types of drugs are called opioids.
Majumdar’s study found that unlike morphine, a synthetic compound derived from kratom (mitragynine pseudoindoxyl) does not lead to harmful side effects like slowed breathing — called respiratory depression — constipation. and physical dependence. Since most deaths from opioid overdose are because of respiratory depression, he believes kratom merits further study to see if some of its compounds can be harnessed for medical benefits that are potentially less addictive.
“I’m not a kratom advocate,” Majumdar says. “I’m not going to say it is a solution for everything, but there is early promise and scheduling is premature in my humble opinion.”
Kratom remains poorly understood, says Edward W. Boyer, MD, PhD, a professor of emergency medicine at the University of Massachusetts Medical School. He knows of a case where a man successfully treated his opioid withdrawal with kratom.
“Most people with opioid withdrawal have abdominal pain. diarrhea. dysphoria.
“This guy really only had a runny nose. and that is pretty remarkable,” Boyer says. “I’m not willing to say [kratom] is great for everyone. I’m just ready to say that is pretty interesting and it should probably be studied more in a controlled way.”
Walter C. Prozialeck, PhD, chairman of the department of pharmacology at Midwestern University in Illinois, analyzed about 100 studies on kratom. He says one major question remains: How addictive is kratom?
Anecdotal reports suggest it is less addictive than opioids, but he says many companies in the U.S. advertise it as a legal high. Several Southeast Asian countries have outlawed it because of addiction concerns.
Prozialeck’s review also found that in almost every case of reported kratom side effects, there were other things involved, like other drugs or health conditions. And since it’s been sold as an herbal supplement, kratom hasn’t received the same amount of governmental oversight as an approved drug.
“So we go from no regulation at all to a total ban. It seems like there could be some middle ground somewhere,” Prozialeck says.
Given all these questions, Prozialeck says doctors aren’t likely to recommend kratom to patients. But he says many in the scientific community do support more research on the drug, especially given the nation’s opioid epidemic.
“If it lived up to its billing, some of the compounds in kratom could be useful at least as the basis for the development of better drugs that would treat pain without the addictive benefit of opioids. That would be an amazing advance in pain management,” Prozialeck says. “But nobody knows how research will turn out. It could be a dead end. The biggest negative of the DEA ban is it will stifle any research in this area.”
After the public comment period expires, the DEA could proceed with banning kratom, which would trigger another comment period. It could decide to temporarily make kratom a schedule 1 drug. Or it could decide to take no action.
The DEA has reversed a scheduling decision once in 2004, on a drug called TFMPP, spokesman Russ Baer says. TFMPP is used as a legal alternative to ecstasy.
WebMD Health News Reviewed by Brunilda Nazario, MD on September 16, 2016
Edward W. Boyer, MD, PhD, University of Massachusetts Medical School, Worcester, MA.
Walter C. Prozialeck, PhD, Midwestern University, Downers Grove, IL.
Saruta Majumdar, PhD, Memorial Sloan-Kettering Cancer Center, New York.
Petition.whitehouse.gov: “Please do not make Kratom a Schedule I Substance.”
Boyer, E. Addiction. June 2008.
Prozialeck, W. The Journal of the American Osteopathic Association. December 2012.
Majumdar, S. Journal of Medicinal Chemistry. Sept. 2, 2016.
Centers for Disease Control and Prevention, Morbidity and Mortality Weekly Report, July 29, 2016 “Notes from the Field: Kratom (Mitragyna speciosa) Exposures Reported to Poison Centers — United States, 2010–2015.
U.S. Drug Enforcement Administration, Drugs of Abuse: A DEA resource guide and “DEA Announces Intent to Schedule Kratom.”
Russ Baer, spokesman, DEA.
Huffington Post: “Congress Calls Out DEA For Unilateral Move To Expand The War On Drugs.”
Federal Register: “Withdrawal of Notice of Intent to Temporarily Place Mitragynine and 7- Hydroxymitragynine into Schedule I.”
News release, the American Kratom Association, and the Botanical Education Alliance.
© 2016 WebMD, LLC. All rights reserved.